BTI
RXRX icon

Blue Trust Inc’s Recursion Pharmaceuticals RXRX Stock Holding History

Blue Trust Inc’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Buy
324
+150
+86% +$499 ﹤0.01% 2267
2026
Q1 		$534 Buy
+174
New +$672 ﹤0.01% 2336
2025
Q2 		– Sell
-1,382
Closed -$7.31K – 2586
2025
Q1 		$7.31K Hold
1,382
– – ﹤0.01% 2017
2024
Q4 		$9.34K Buy
1,382
+1,296
+1,507% +$8.71K ﹤0.01% 1958
2024
Q3 		$645 Buy
86
+53
+161% +$380 ﹤0.01% 2763
2024
Q2 		$329 Buy
+33
New +$288 ﹤0.01% 2638
2023
Q2 		– Sell
-22
Closed – – 2453
2023
Q1 		$0 Buy
+22
New +$175 ﹤0.01% 2581

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Blue Trust Inc's RXRX Position: Q2 2026 in Review

Blue Trust Inc increased its Recursion Pharmaceuticals (RXRX) stake by 86% in Q2 2026, buying an estimated $499 and bringing the position to 324 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Blue Trust Inc first reported a position in RXRX in Q1 2023 and has held it in 7 quarters since. The position peaked at $9.34K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Blue Trust Inc held 324 shares of Recursion Pharmaceuticals worth $1.19K as of Q2 2026.
  • Blue Trust Inc bought 150 Recursion Pharmaceuticals shares in Q2 2026, an estimated $499.
  • Recursion Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2267 holding.
  • Blue Trust Inc first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • Blue Trust Inc's Recursion Pharmaceuticals position peaked at $9.34K in Q4 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.